ALK and non-small cell lung carcinoma: These phase II clinical trials (NCT01685060 and NCT01685138) aim to assess the overall response rate in patients with NSCLC and the ALK rearrangement, with one testing patients previously treated with crizotinib and the other testing treatment-naive patients (Novartis Pharmaceutics, 2012a, 2012b).